抗 SARS-CoV-2 再利用药物数据库：临床药理学考虑。
Anti-SARS-CoV-2 Repurposing Drug Database: Clinical Pharmacology Considerations.
机构信息
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
出版信息
CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):973-982. doi: 10.1002/psp4.12681. Epub 2021 Aug 1.
A critical step to evaluate the potential in vivo antiviral activity of a drug is to connect the in vivo exposure to its in vitro antiviral activity. The Anti-SARS-CoV-2 Repurposing Drug Database is a database that includes both in vitro anti-SARS-CoV-2 activity and in vivo pharmacokinetic data to facilitate the extrapolation from in vitro antiviral activity to potential in vivo antiviral activity for a large set of drugs/compounds. In addition to serving as a data source for in vitro anti-SARS-CoV-2 activity and in vivo pharmacokinetic information, the database is also a calculation tool that can be used to compare the in vitro antiviral activity with in vivo drug exposure to identify potential anti-SARS-CoV-2 drugs. Continuous development and expansion are feasible with the public availability of this database.
评估药物潜在体内抗病毒活性的关键步骤是将体内暴露与体外抗病毒活性联系起来。抗 SARS-CoV-2 再利用药物数据库是一个包含体外抗 SARS-CoV-2 活性和体内药代动力学数据的数据库，旨在促进从体外抗病毒活性推断出大量药物/化合物的潜在体内抗病毒活性。除了作为体外抗 SARS-CoV-2 活性和体内药代动力学信息的数据源外，该数据库还是一个计算工具，可用于比较体外抗病毒活性与体内药物暴露，以确定潜在的抗 SARS-CoV-2 药物。随着该数据库的公开，持续开发和扩展是可行的。
Zotero 插件